한글목차

세계의 폐암 진단 시장은 2024년에 15억 4,000만 달러로 평가되었으며, 2030년까지 CAGR 6.99%로 성장하여 23억 1,000만 달러에 달할 것으로 예측됩니다.

세계 폐암 진단 시장은 폐암의 조기 발견과 정확한 특성 파악을 위해 사용되는 다양한 기술과 절차를 포괄하고 있습니다. 시장 성장은 주로 전 세계 폐암 발생률의 증가와 조기 검진의 이점에 대한 인식이 높아짐에 따라 주도되고 있습니다.

주요 시장 촉진요인

전 세계적으로 증가하고 있는 폐암 발생률은 진단 시장의 기본적인 촉진제입니다. 이러한 신규 환자 증가는 효과적인 치료 계획과 환자 예후 개선에 필수적인 조기 발견과 정확한 병기 결정을 위한 진단 능력의 확대를 직접적으로 요구하고 있습니다.

주요 시장 과제

첨단 진단 기술에 필요한 막대한 자본 투자는 전 세계 폐암 진단 시장 확대에 큰 걸림돌로 작용하고 있습니다. 최첨단 영상 진단 장비, 고급 분자 프로파일링 플랫폼, 전문 실험실 인프라와 관련된 높은 구매 비용, 설치 비용 및 지속적인 유지보수 비용은 이러한 기술의 광범위한 사용과 보급을 크게 제한하고 있습니다.

주요 시장 동향

전 세계 폐암 검진 프로그램의 확대는 질병의 조기 발견을 체계적으로 증가시킴으로써 진단 시장을 주도하는 중요한 추세입니다. 업데이트된 가이드라인을 통해 점점 더 많은 사람들이 저선량 컴퓨터 단층촬영(LDCT) 검진을 받을 수 있는 인구가 확대되고, 영상 진단 장비, 숙련된 방사선 전문의 및 후속 진단 절차에 대한 수요가 증가하고 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 폐암 진단 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 종류별(소세포폐암, 비소세포폐암)
  • 검사별(영상 검사, 생검, 객담세포진, 분자 검사, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 폐암 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 폐암 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 폐암 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 폐암 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 폐암 진단 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 폐암 진단 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Sanofi S.A.
• Roche Diagnostics Corporation
• BioMerieux SA
• Qiagen N.V.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Illumina Inc.
• Johnson & Johnson
• Abbott Laboratories Inc.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

The Global Lung Cancer Diagnostics Market, valued at USD 1.54 Billion in 2024, is projected to experience a CAGR of 6.99% to reach USD 2.31 Billion by 2030. The Global Lung Cancer Diagnostics Market encompasses a diverse range of technologies and procedures utilized for the early detection and precise characterization of lung cancer. Market growth is primarily driven by the escalating global incidence of lung cancer and heightened awareness surrounding the benefits of early screening.

Key Market Drivers

The increasing global incidence of lung cancer represents a fundamental driver for the diagnostics market. This rising number of new cases directly necessitates expanded diagnostic capabilities for early detection and precise staging, which are vital for effective treatment planning and improved patient outcomes. The escalating incidence creates continuous demand on healthcare systems for accessible diagnostic tools, encompassing advanced imaging modalities and comprehensive molecular profiling. According to the American Cancer Society and the International Agency for Research on Cancer, in April 2024, "Global Cancer Statistics, 2024" reported an estimated 2.5 million cases of lung cancer were newly diagnosed worldwide in 2022.

Key Market Challenges

The substantial capital investment required for advanced diagnostic technologies poses a notable challenge to the expansion of the Global Lung Cancer Diagnostics Market. The high acquisition, installation, and ongoing maintenance costs associated with state-of-the-art imaging equipment, advanced molecular profiling platforms, and specialized laboratory infrastructure significantly limit their widespread accessibility and adoption. This financial barrier is particularly impactful in emerging economies, where healthcare budgets are often constrained and robust medical infrastructure is less developed.

Key Market Trends

The expansion of global lung cancer screening programs represents a significant trend driving the diagnostics market by systematically increasing the early detection of the disease. These initiatives, increasingly backed by updated guidelines, broaden the eligible population for low-dose computed tomography (LDCT) screening, leading to a greater demand for imaging equipment, skilled radiologists, and subsequent diagnostic procedures. For instance, according to the American Cancer Society, in June 2024, a study found that the up-to-date lung cancer screening prevalence in the United States was 18.1% in 2022, highlighting ongoing efforts to improve screening rates. This programmatic expansion ensures that more individuals at high risk are undergoing regular examinations, facilitating earlier diagnosis and intervention.

Key Market Players

• Sanofi S.A.
• Roche Diagnostics Corporation
• BioMerieux SA
• Qiagen N.V.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Illumina Inc.
• Johnson & Johnson
• Abbott Laboratories Inc.

Report Scope:

In this report, the Global Lung Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Diagnostics Market, By Type:

• Small Cell Lung Cancer
• Non-small Cell Lung Cancer

Lung Cancer Diagnostics Market, By Test:

• Imaging Test
• Biopsy
• Sputum Cytology
• Molecular Test
• Others

Lung Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Diagnostics Market.

Available Customizations:

Global Lung Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer)
  • 5.2.2. By Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Lung Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Test
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Test
  • 6.3.2. Canada Lung Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Test
  • 6.3.3. Mexico Lung Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Test

7. Europe Lung Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Test
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Test
  • 7.3.2. France Lung Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Test
  • 7.3.3. United Kingdom Lung Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Test
  • 7.3.4. Italy Lung Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Test
  • 7.3.5. Spain Lung Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Test

8. Asia Pacific Lung Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Test
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Test
  • 8.3.2. India Lung Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Test
  • 8.3.3. Japan Lung Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Test
  • 8.3.4. South Korea Lung Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Test
  • 8.3.5. Australia Lung Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Test

9. Middle East & Africa Lung Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Test
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Test
  • 9.3.2. UAE Lung Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Test
  • 9.3.3. South Africa Lung Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Test

10. South America Lung Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Test
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Test
  • 10.3.2. Colombia Lung Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Test
  • 10.3.3. Argentina Lung Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Test

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sanofi S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Roche Diagnostics Corporation
• 15.3. BioMerieux SA
• 15.4. Qiagen N.V.
• 15.5. Agilent Technologies, Inc.
• 15.6. Thermo Fisher Scientific Inc.
• 15.7. AstraZeneca plc
• 15.8. Illumina Inc.
• 15.9. Johnson & Johnson
• 15.10. Abbott Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer